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ABSTRACT
Introduction: Robust immunity is essential for further human exploration of the solar system beyond
Earth’s orbit. Spaceflight has been associated with immune perturbations and latent viral reactivation.
However, logistical constraints have restricted many of these studies to simple pre- and post-flight
measures, which are greatly confounded by the stressors associated with launch, landing and readaptation to the 1G environment. More in-flight immune data are required particularly during longduration (3-6 months) spaceflight missions. This study examined the effects of spaceflight on plasma
antimicrobial proteins (AMPs) and reactivation of latent herpesviruses.
Methods: Plasma, saliva and urine samples were obtained from 20 crewmembers who spent ~6-months
on the International Space Station (ISS). Samples were collected 180 and 45-days before launch, in-flight
(at ‘early, ‘mid’ and ‘late’ stages of the mission), immediately upon return to Earth (R+0) and 30 days
following return (R+30). Plasma LL-37, HNP 1-3 and lysozyme concentrations were determined by
ELISA. Saliva Epstein-Barr virus (EBV), varicella zoster virus (VZV) and urine cytomegalovirus (CMV)
DNA levels were quantified by Real-Time PCR. Maximum likelihood linear mixed models (LMM) were
used to determine main effects of time (pre-flight, in-flight, R+0 and R+30), and EBV, VZV and CMV viral
shedding status (shedding or non-shedding) on the concentration of each AMPs. Results: Lower plasma
levels of LL-37 were found at R+0, compared to pre-flight, in-flight and R+30 (-80.6%, -80.2% and -73.49%
respectively; p < 0.01). Plasma HNP 1-3 levels were elevated above pre-flight level during flight, at R+0
and R+30 (+24%, +40% and +17% respectively; p < 0.01). Only those crewmembers found to shed CMV
had a significant reduction in plasma LL-37 at R+0 (p < 0.05). Similarly, crewmembers found to shed
VZV at R+0 had lower HNP 1-3 concentrations than crewmembers who did not shed VZV (-68.9%; p <
0.01). Finally, only those crewmembers who shed EBV had increased plasma levels of HNP 1-3 at R+0 (p
< 0.01). Plasma lysozyme levels were unaffected by spaceflight or latent viral shedding. Conclusion:
Long-duration spaceflight alters plasma LL-37 and HNP 1-3 levels and are linked to the reactivation of
latent herpesviruses. The in-flight changes observed for HNP 1-3 indicate that certain immune
perturbations may be independent of launch/landing stress. Future studies are required to determine if
spaceflight induced immune dysregulation increases the risk of an adverse health event before
exploration-class planetary missions (i.e. to Mars) can be considered.

